How Much Does Crestor (Rosuvastatin) Cost in Indiana in 2026?

Brand vs. Generic: The Price Gap in Indiana

Generic rosuvastatin has turned one of the most expensive statins into one of the cheapest. AstraZeneca's branded Crestor still carries a list price near $290 per month, but very few Hoosiers pay that figure. Generic rosuvastatin calcium tablets, available since 2016 after patent expiry, average roughly $15 per month across Indiana retail pharmacies in 2026.

That price difference matters clinically because rosuvastatin is the most potent statin per milligram on the market. The 2018 AHA/ACC cholesterol guideline classifies rosuvastatin 20 to 40 mg as high-intensity statin therapy, capable of lowering LDL-C by 50% or more. Atorvastatin 40 to 80 mg is the only other statin in that high-intensity tier. For patients who need aggressive LDL reduction, generic rosuvastatin often delivers the best value: maximal potency at a generic price point.

Indiana has over 1,400 retail pharmacy locations, including major chains like CVS, Walgreens, and Kroger, along with independent pharmacies. Prices vary by 20 to 40% across these outlets even for the same generic, so comparison shopping or using a discount card can drop costs below the $15 average. GoodRx and RxSaver routinely list 30-day supplies of rosuvastatin 10 mg or 20 mg at $4, $8 at select Indiana locations.

Indiana Medicaid and Rosuvastatin: A Coverage Gap

Indiana Medicaid, administered through managed care plans like Anthem, CareSource, MDwise, and MHS, does not cover rosuvastatin for general hyperlipidemia or primary ASCVD prevention. Coverage is limited to patients with type 2 diabetes. This restriction creates a meaningful access gap, since the JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg reduced major cardiovascular events by 44% in patients with elevated hsCRP but normal LDL-C, a population that extends well beyond diabetes.

If you have Indiana Medicaid and need a statin for lipid management alone, your prescriber will likely need to select atorvastatin, simvastatin, or pravastatin, all of which sit on the preferred drug list for broader indications. Alternatively, your physician can submit a prior authorization request arguing medical necessity for rosuvastatin specifically. Approval is not guaranteed.

For Medicaid enrollees with type 2 diabetes and dyslipidemia, rosuvastatin is covered. The 2022 ADA Standards of Care recommend moderate- or high-intensity statin therapy for all adults with diabetes aged 40, 75, regardless of baseline LDL. Rosuvastatin 10 mg (moderate-intensity) or 20 to 40 mg (high-intensity) satisfies that recommendation.

Roughly 1.1 million Hoosiers are enrolled in Medicaid or the Healthy Indiana Plan (HIP 2.0). For the subset with cardiovascular risk factors but no diabetes diagnosis, the Medicaid coverage exclusion may force suboptimal statin selection or out-of-pocket generic purchases.

Commercial Insurance Coverage Across Indiana

Most commercial health plans in Indiana, including those from Anthem Blue Cross Blue Shield, UnitedHealthcare, Cigna, and Aetna, cover generic rosuvastatin at Tier 1 or Tier 2 copay levels. Typical copays range from $0 to $15 per month, depending on the plan design. Brand-name Crestor sits on Tier 3 (preferred brand) or non-preferred tiers, carrying copays of $35, $75 or higher.

The 2018 AHA/ACC guideline recommends shared clinician-patient decision-making about statin intensity, accounting for both ASCVD risk and medication access. If your plan charges a high copay for rosuvastatin but covers atorvastatin at $0, switching to atorvastatin 40 mg (an equivalent high-intensity option) is clinically reasonable. However, some patients tolerate rosuvastatin better due to its lower CYP3A4 interaction profile. Your prescriber can document this rationale in a formulary exception request if needed.

Indiana state employees covered through the Indiana Public Employees' Health Plan generally access generic rosuvastatin with a $10 or lower copay at in-network pharmacies. Retirees on Medicare Part D plans should check their specific formulary, as coverage tiers and donut-hole costs vary by plan.

The AstraZeneca Savings Card and Other Discount Programs

AstraZeneca offers a branded Crestor savings card that can reduce copays for commercially insured patients to as low as $3 per month. The card is not available to patients on Medicare, Medicaid, Tricare, or other government-funded programs. Given that generic rosuvastatin already averages $15 per month cash pay in Indiana, the savings card is mainly relevant for patients whose physician specifically prescribes brand Crestor and whose insurer places it on a high copay tier.

For uninsured Hoosiers, several options exist. The AstraZeneca Patient Assistance Program (AZ&Me) provides free brand Crestor to patients who earn below 300% of the federal poverty level and lack prescription coverage. Application requires income documentation and a valid prescription.

Pharmacy discount programs offer another route. Kroger, Walmart, and Meijer, all with substantial Indiana footprints, include generic rosuvastatin on $4-per-month or $10-per-90-day generic lists. These programs require no insurance and no income verification. A 90-day supply at $10 works out to roughly $3.33 per month.

Mark Cuban's Cost Plus Drugs prices generic rosuvastatin at $3.60 for a 30-day supply of 10 mg tablets (as of early 2026), plus a flat $5 shipping fee. For patients comfortable with mail-order, this represents one of the lowest all-in costs available to Indiana residents.

Compounded Rosuvastatin in Indiana

Compounded rosuvastatin is legal in Indiana through 503A-licensed compounding pharmacies operating under a valid patient-specific prescription. A 503A pharmacy compounds medications on an individual-patient basis after receiving a prescription, as permitted under Section 503A of the Federal Food, Drug, and Cosmetic Act. Indiana's Board of Pharmacy oversees state-level compounding licensure.

Why would anyone compound a generic drug that already costs $15 or less? Two clinical scenarios arise. First, patients who cannot swallow tablets may need a liquid suspension. Rosuvastatin is not commercially available in liquid form, so a compounding pharmacy can prepare an oral suspension at a specified concentration. Second, patients who need a dose not available in manufactured tablets (e.g., 7.5 mg or 15 mg for dose titration) can have custom-strength capsules compounded.

Compounded formulations are not AB-rated equivalents to manufactured tablets. They do not undergo the same FDA bioequivalence testing required of generic manufacturers. The American College of Cardiology has not issued specific guidance on compounded statins, and most lipid specialists prefer manufactured generics when a patient can use them.

Indiana does not permit 503B outsourcing facilities to distribute compounded rosuvastatin without patient-specific prescriptions unless operating under federal 503B registration. Patients should verify that their compounding pharmacy holds a current Indiana Board of Pharmacy compounding license.

Telehealth Prescribing: Getting Rosuvastatin Without an Office Visit

Indiana permits telehealth prescribing of rosuvastatin. A physician, nurse practitioner, or physician assistant licensed in Indiana can evaluate a patient via synchronous audio-video visit and prescribe a statin based on lab results and cardiovascular risk assessment. No in-person visit is required for an initial statin prescription under Indiana's current telehealth regulations.

This matters for cost in two ways. First, telehealth visits typically cost $20, $75, compared to $150, $300 for an in-person office visit. That lower encounter cost reduces the total annual expense of statin therapy. Second, telehealth expands access in rural Indiana counties where primary care providers are scarce. According to the Health Resources and Services Administration, 33 of Indiana's 92 counties are designated Health Professional Shortage Areas for primary care.

Before prescribing rosuvastatin, a clinician needs a recent lipid panel and, ideally, a 10-year ASCVD risk calculation using the Pooled Cohort Equations. Many telehealth platforms accept lab results from Quest Diagnostics or Labcorp, both of which operate draw sites across Indiana. A basic lipid panel costs $15, $30 through direct-to-consumer lab ordering.

The JUPITER trial enrolled patients with LDL-C <130 mg/dL but hsCRP ≥2.0 mg/L and demonstrated a 44% relative risk reduction in the primary composite endpoint (MI, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death) with rosuvastatin 20 mg versus placebo over a median 1.9 years. That trial established rosuvastatin's role in primary prevention beyond traditional lipid thresholds. A telehealth clinician in Indiana can apply these same evidence-based criteria without requiring a brick-and-mortar visit.

Dose, Efficacy, and Cost-per-LDL-Point Reduction

Rosuvastatin's potency translates to fewer milligrams needed for a given LDL reduction, which has practical cost implications when comparing statins.

At the 10 mg dose, rosuvastatin lowers LDL-C by approximately 46%. At 20 mg, LDL-C drops by roughly 52%. At 40 mg, the reduction reaches about 55%. These figures come from the Crestor prescribing information and align with data from the STELLAR trial, which directly compared rosuvastatin against atorvastatin, simvastatin, and pravastatin across dose ranges.

In Indiana, generic rosuvastatin costs roughly the same regardless of tablet strength. A 30-day supply of 5 mg tablets costs about the same as 40 mg tablets at most pharmacies. This flat pricing means patients can use the most effective dose without a cost penalty. By contrast, brand Crestor pricing can vary by strength at some retail pharmacies.

For a patient with baseline LDL of 160 mg/dL and a treatment goal below 100 mg/dL (a reduction of at least 38%), rosuvastatin 5 mg would be sufficient. That represents roughly $0.50 per day of therapy, or about $0.01 per percentage-point LDL reduction per day. Few interventions in cardiovascular medicine match that cost-effectiveness.

The 2013 ACC/AHA Pooled Cohort Equations help determine which patients benefit most from statin therapy. Adults aged 40, 75 with a 10-year ASCVD risk ≥7.5% are candidates for moderate- to high-intensity statin therapy. At Indiana's generic pricing, the medication cost for this evidence-based intervention is negligible compared to the cost of a single cardiovascular hospitalization, which averages over $20,000.

Side Effects and Monitoring Costs to Factor In

Statin therapy requires periodic lab monitoring, and those costs add to the total expense of treatment. The ACC/AHA guideline recommends a fasting lipid panel 4 to 12 weeks after starting or adjusting statin therapy, then every 3 to 12 months thereafter. A hepatic function panel at baseline is also recommended.

In Indiana, a fasting lipid panel at a commercial lab costs $20, $40 through direct-pay ordering, or is covered at $0 under most insurance plans as part of preventive screening. Adding a CMP (which includes liver enzymes) costs another $10, $25 cash pay.

Rosuvastatin's side-effect profile is comparable to other statins. Myalgia (muscle aches without CK elevation) occurs in 5 to 10% of patients across statin classes. True statin-associated muscle symptoms (SAMS) leading to discontinuation affect roughly 7 to 29% of patients depending on the definition used, according to a 2015 meta-analysis in the European Heart Journal. If a patient develops myalgia on rosuvastatin, switching to a lower dose or alternate-day dosing is an option that preserves LDL reduction while reducing muscle symptoms.

New-onset diabetes is a recognized statin class effect. The JUPITER trial reported a 0.6% absolute increase in physician-reported diabetes with rosuvastatin 20 mg versus placebo over 1.9 years. The cardiovascular benefit substantially outweighed this risk in the trial population. As Dr. Paul Ridker, the JUPITER trial principal investigator, stated: "The cardiovascular benefits of rosuvastatin therapy far outweigh any diabetes hazard, particularly among those at elevated vascular risk."

How Indiana Compares to Neighboring States

Generic rosuvastatin pricing in Indiana tracks closely with neighboring Midwest states. Ohio, Illinois, Michigan, and Kentucky all report average generic rosuvastatin prices between $12 and $18 per month at retail pharmacies. Indiana sits near the middle of that range.

The key differentiator is Medicaid coverage. Illinois Medicaid covers rosuvastatin for hyperlipidemia broadly, without the diabetes-only restriction that Indiana imposes. Ohio Medicaid also covers rosuvastatin as a preferred formulary agent for lipid management. This means Indiana Medicaid enrollees have more limited statin options than their counterparts in neighboring states.

For commercially insured patients, the interstate price differences are minimal. Generic rosuvastatin copays are driven primarily by formulary tier placement, which varies by insurer rather than by state. A Hoosier with Anthem BCBS commercial coverage pays essentially the same rosuvastatin copay as an Anthem member in Ohio.

Indiana's 7% state sales tax does not apply to prescription medications, which keeps out-of-pocket costs lower than they would be in states that tax prescriptions. This exemption applies to both brand and generic medications filled at Indiana pharmacies.